- Home
- NEPH vs KZIA Comparison
NEPH vs KZIA Comparison
Compare NEPH & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEPH
- KZIA
- Stock Information
- Founded
- NEPH 1997
- KZIA 1994
- Country
- NEPH United States
- KZIA Australia
- Employees
- NEPH N/A
- KZIA N/A
- Industry
- NEPH Medical/Dental Instruments
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- NEPH Health Care
- KZIA Health Care
- Exchange
- NEPH Nasdaq
- KZIA Nasdaq
- Market Cap
- NEPH 15.9M
- KZIA 18.7M
- IPO Year
- NEPH 2004
- KZIA 1999
- Fundamental
- Price
- NEPH $1.54
- KZIA $3.02
- Analyst Decision
- NEPH Buy
- KZIA Strong Buy
- Analyst Count
- NEPH 1
- KZIA 1
- Target Price
- NEPH $5.00
- KZIA $20.00
- AVG Volume (30 Days)
- NEPH 9.8K
- KZIA 85.9K
- Earning Date
- NEPH 11-07-2024
- KZIA 01-03-2025
- Dividend Yield
- NEPH N/A
- KZIA N/A
- EPS Growth
- NEPH N/A
- KZIA N/A
- EPS
- NEPH N/A
- KZIA N/A
- Revenue
- NEPH $13,546,000.00
- KZIA $1,655,324.00
- Revenue This Year
- NEPH N/A
- KZIA $806.89
- Revenue Next Year
- NEPH $9.13
- KZIA N/A
- P/E Ratio
- NEPH N/A
- KZIA N/A
- Revenue Growth
- NEPH 0.03
- KZIA 248000.00
- 52 Week Low
- NEPH $1.36
- KZIA $1.90
- 52 Week High
- NEPH $4.04
- KZIA $15.80
- Technical
- Relative Strength Index (RSI)
- NEPH 47.64
- KZIA 30.94
- Support Level
- NEPH $1.53
- KZIA $2.78
- Resistance Level
- NEPH $1.64
- KZIA $4.20
- Average True Range (ATR)
- NEPH 0.06
- KZIA 0.55
- MACD
- NEPH -0.01
- KZIA -0.13
- Stochastic Oscillator
- NEPH 37.50
- KZIA 9.92
About NEPH Nephros Inc.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.